Skip to content
Markets News
Earnings1 min read

GSK slides despite higher revenue as vaccine sales weaken

Makkler Newsroom
October 28, 2026 · Based on reporting by finanzen.net, City A.M., The Guardian

Quarterly turnover rose 5% at constant currencies, but lower vaccine sales and restructuring costs weighed on investors.

Key takeaways

  • Third-quarter turnover rose 5% at constant currency rates to £8.9bn.
  • Vaccine sales fell 2% to £2.6bn.
  • Pre-tax profit declined 19% to £1.9bn.
  • GSK maintained its annual forecasts.

GSK shares fell as much as 7% on Wednesday after the drugmaker reported a 2% drop in vaccine sales, despite higher quarterly revenue. Turnover rose 5% at constant currency rates to £8.9bn.

Sales of HIV, cancer and lupus medicines supported growth, while the vaccine business brought in £2.6bn. Meningitis vaccine sales rose 12%, but sales of shingles vaccine Shingrix and RSV vaccine Arexvy fell.

Pre-tax profit declined 19% to £1.9bn in the July-to-September quarter. GSK also reported £318m in restructuring charges, with further charges expected.

Chief executive Luke Miels said the company was slightly ahead of its three-year plan to save £1.9bn a year. The restructuring is expected to cost £2.4bn, with most charges due this year and next.

GSK maintained its annual forecasts. The company expects research and development spending to grow faster than sales and aims to begin 22 late-stage studies by year-end.

As of 12:31 UTC on Wednesday, GSK traded at 1,813.5 GBp, down 5.72% from the previous close.

Topics

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.